Form 4: Evolent Health Director Kim Keck Granted Over 21,000 Restricted Stock Units

Evolent Health, Inc. (EVH) Director Kim Keck was granted 21,979 restricted stock units (RSUs) on June 5, 2025, as part of the company's incentive compensation plan.

Summary

• Kim Keck, a Director of Evolent Health, Inc. (EVH), acquired 21,979 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• The transaction occurred on June 5, 2025, with a reported price of $0 per unit, typical for RSU grants.
• Following this transaction, Ms. Keck beneficially owns a total of 61,501 shares of Class A Common Stock.
• These RSUs were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The securities are set to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent upon Ms. Keck's continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a routine equity grant to a director, aligning their interests with shareholders. It does not indicate any significant operational or financial changes, hence not highly impactful on its own.

Positives

• The grant of restricted stock units to Director Kim Keck aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The transaction is part of a pre-existing, approved incentive compensation plan, indicating a structured approach to executive and director remuneration.

Future Outlook

The document does not provide a general future outlook for the company, but it indicates a future vesting event for the granted restricted stock units on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting.

Industry Context

This Form 4 filing is a routine disclosure of director compensation in the form of equity, a common practice across various industries, including healthcare technology, to incentivize long-term commitment and align management interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a standard practice in publicly traded companies, including those in the healthcare technology sector like Evolent Health.
• The use of a pre-approved omnibus incentive compensation plan (Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan) is consistent with corporate governance best practices for equity awards.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Kim Keck, a director of Evolent Health, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The restricted stock units are expected to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, subject to continued service.

Key Dates

Keywords

Evolent Health, EVH, SEC Form 4, Restricted Stock Units, RSU grant, Insider transaction, Director compensation, Equity compensation, Corporate governance, Incentive plan